Next Article in Journal
Cyclin D1 Expression and the Inhibitory Effect of Celecoxib on Ovarian Tumor Growth in Vivo
Next Article in Special Issue
Lipid Based Therapy for Ulcerative Colitis—Modulation of Intestinal Mucus Membrane Phospholipids as a Tool to Influence Inflammation
Previous Article in Journal
Determination of the Thermodegradation of deoxyArbutin in Aqueous Solution by High Performance Liquid Chromatography
Previous Article in Special Issue
The Effect of Exercise on the Skeletal Muscle Phospholipidome of Rats Fed a High-Fat Diet
Article Menu

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2010, 11(10), 3988-3998;

Lysophosphatidic Acid Level and the Incidence of Silent Brain Infarction in Patients with Nonvalvular Atrial Fibrillation

Department of Neurology, Wendeng Center Hospital of Weihai, the Affiliated Hospital of Weifang Medical College, Weihai, Shandong 264400, China
Author to whom correspondence should be addressed.
Received: 12 August 2010 / Revised: 25 September 2010 / Accepted: 12 October 2010 / Published: 19 October 2010
(This article belongs to the Special Issue Phospholipids: Molecular Sciences)
Full-Text   |   PDF [181 KB, uploaded 19 June 2014]


Lysophosphatidic acid (LPA), which is proposed to play an important role in normal physiological situations such as wound healing, vascular tone, vascular integrity and reproduction, may be involved in the etiology of some diseases such as atherosclerosis, cancer, obesity or myocardial infarction. Abnormal findings, including silent brain infarction (SBI), are frequently observed by magnetic resonance imaging (MRI) in patients with nonvalvular atrial fibrillation (NVAF). However, whether there is a relationship between LPA level and the prevalence of SBI has not been extensively studied. In the present study, the association between them was investigated. 235 patients with NVAF, 116 cases of SBI without NVAF and 120 cases of healthy volunteers (control group), who did not receive any antithrombotic therapy, were enrolled in this study. Plasma LPA levels in the NVAF with SBI group were significantly higher than that in the control group (p < 0.01), NVAF without SBI group (p < 0.01) and SBI without NVAF group (p < 0.01). The LPA levels are lower in the control group than in the NVAF without SBI and SBI without NVAF groups (p < 0.01), however, the latter two groups did not significantly differ from each other for LPA levels (p > 0.05) There were significant differences in the positive rate of platelet activation between each of the groups (p < 0.01). The positive rate of platelet activation was significantly higher in the NVAF with SBI group. We suggest that LPA might be a novel marker for estimation of the status of platelet activation and the risk factor for SBI onset in NVAF patients. We expected that plasma LPA levels could predict the occurrence of SBI in NVAF patients. View Full-Text
Keywords: atrial fibrillation; lysophospholipids; ischemic stroke; platelet activation atrial fibrillation; lysophospholipids; ischemic stroke; platelet activation
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Li, Z.-G.; Yu, Z.-C.; Yu, Y.-P.; Ju, W.-P.; Wang, D.-Z.; Zhan, X.; Wu, X.-J.; Zhou, L. Lysophosphatidic Acid Level and the Incidence of Silent Brain Infarction in Patients with Nonvalvular Atrial Fibrillation. Int. J. Mol. Sci. 2010, 11, 3988-3998.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top